<DOC>
	<DOCNO>NCT02583659</DOCNO>
	<brief_summary>This prospective cohort study aim observe efficacy safety first-line combine chemotherapy advance gastric cancer ( AGC ) Chinese population .</brief_summary>
	<brief_title>The First-line Combined Chemotherapy Advanced Gastric Cancer : A Prospective Observational Clinical Study</brief_title>
	<detailed_description>1 . Establish clinical database advance gastric cancer patient treat first-line combined chemotherapy Tongji hospital . 1.1.Data include age , gender , smoke state , karnofsky performance score（KPS） , disease history , clinical stage , primary tumor site , metastasis site , surgery , first-line chemotherapy , therapy failure first-line treatment , radiotherapy , toxicity , survival time , time free progress , response collect . 1.2.The peripheral blood sample collect biomarker reserch . 2 . Kaplan-Meier Cox model use analyze overall survival ( OS ) progression-free survival ( PFS ) advance gastric cancer . 3 . Extract Deoxyribonucleic acid（DNA） peripheral blood research biomarkers relate first-line combined chemotherapy AGC .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Histopathology cytopathology proven gastric cancer gastroesophageal adenocarcinoma ; 2 . Unresectable locally advanced , recurrent , metastasis disease； 3 . Chemotherapynaive disease progress least 6 month adjuvant chemotherapy complete . 4 . Life expectancy least 3 month ; 5 . ECOG score 02 ; 6 . Voluntarily sign informed consent . Exclusion criterion : 1 . Previously treat firstline chemotherapy ; 2 . Firstline chemotherapy single drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>First-line chemotherapy</keyword>
	<keyword>Biomarker</keyword>
</DOC>